P105 Computational Design of IgG-like Tetra-Specific Antibody Targeting EGFR/VEGF/PD-1/CTLA-4 Against NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.10.131
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P16-05. Upregulation of PD-1 and CTLA-4 on HIV-specific T Cells in HIV-infected Infants

Retrovirology
VirologyInfectious Diseases
2009English

CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers

International Journal of Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2018English

Intestinal Microbiota Predict Response and Toxicities During Anti-Pd-1/Anti-Ctla-4 Immunotherapy

Pathology
Forensic MedicinePathology
2020English

Enhancement of Oncolytic Activity of oHSV Expressing IL-12 and Anti PD-1 Antibody by Concurrent Administration of Exosomes Carrying CTLA-4 miRNA

2019English

The Efficacy and Safety of Combination of PD-1 and CTLA-4 Inhibitors: A Meta-Analysis

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2019English

Ipilimumab: An Anti-Ctla-4 Antibody for Metastatic Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2011English

PD-1- And CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

Science Translational Medicine
Medicine
2013English

Rationale for Targeting VEGF, FGF, and PDGF for the Treatment of NSCLC

OncoTargets and Therapy
OncologyPharmacology
2011English

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy